Fosun Pharma’s development history can be broadly divided into the following four stages, illustrating its transformation from a startup into a global innovative healthcare group:
I. Founding and Foundation Stage (1994 – 1998)
- Startup Background: In 1994, the predecessor of Fosun Pharma (Shanghai Fosun Industrial Co., Ltd.) was established. The company initially focused on pharmaceutical R&D and technical services, beginning to accumulate technical expertise in the Chinese pharmaceutical market.
- Entry into Capital Markets: In 1998, the company successfully listed on the Main Board of the Shanghai Stock Exchange (Stock Code: 600196.SH). This marked its entry into the fast lane of capital market development, providing the necessary funding for subsequent mergers and industrial integration.
II. Industrial Integration and Diversification Stage (1999 – 2011)
- Full Industry Chain Layout: During this period, the company adopted an aggressive merger and acquisition strategy. By integrating various pharmaceutical manufacturers and research institutions, it established a comprehensive pharmaceutical industry chain.
- Strategic Cooperation: In 2003, the company partnered with China National Pharmaceutical Group (Sinopharm) to establish “Sinopharm Group,” successfully expanding into the pharmaceutical commercial distribution sector. This allowed the company to possess not only manufacturing capabilities but also powerful sales and distribution networks.
- Market Expansion: Through acquisitions and restructuring (such as Guilin Pharma), the company strengthened its international competitiveness in anti-malarial drugs and specialty active pharmaceutical ingredients (APIs).
III. Innovation-Driven and Global Deepening Stage (2012 – 2020)
- Hong Kong IPO: In 2012, Fosun Pharma listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 02196.HK), achieving an “A+H” dual-listing structure and accelerating its global expansion.
- R&D Transformation: The company shifted its strategic focus to being “innovation-driven,” significantly increasing R&D investment. By combining internal R&D (such as the biological drug layout of Henlius) with licensed-in products, it built an innovative drug R&D system encompassing small molecule drugs, antibody drugs, and cell immunotherapy (CAR-T).
- Global Operational Capability: The acquisition of companies such as India’s Gland Pharma marked the company’s ability to maintain mature overseas manufacturing and supply chain operational capabilities.
IV. Global Operations and Digital Intelligence Stage (2021 – Present)
- Global Pandemic Response and Vaccine Cooperation: During the 2020 pandemic, the company established a strategic partnership with Germany’s BioNTech to introduce the mRNA COVID-19 vaccine (Comirnaty). This not only demonstrated its ability to integrate international resources but also elevated its own technology platform to an international standard.
- Deepening Core Areas: The company currently focuses on key therapeutic areas such as oncology, immunology, inflammation, and the nervous system. It is implementing the “4IN” strategy (Innovation, Internationalization, Intelligentization, and Integration), actively leveraging AI for drug discovery, and further optimizing its global operational network to become a global leader in medical innovation integration.
Sources:
Fosun Pharma’s business model and strategic core focus on transforming the company into a research- and innovation-driven global pharmaceutical industry ecosystem. This can be broken down into two main dimensions: business model and development strategy.
I. Business Model: Medical and Healthcare Industry Ecosystem
Fosun Pharma’s revenue model relies not on single-product sales, but on building a full-industry-chain ecosystem to generate diversified revenue:
- Full Industry Chain Synergy:
- R&D and Manufacturing: Through internal R&D, co-development, and licensing-in, the company secures high-value innovative drug patents and manufacturing capabilities.
- Commercialization and Distribution: Leveraging its stake in Sinopharm’s network, the company ensures its products rapidly cover China’s massive pharmaceutical market, achieving scaled commercial landing.
- Healthcare Services: It deploys medical institutions and health management services to form a closed-loop ranging from prevention, diagnosis, and treatment to rehabilitation, enhancing the group’s influence among end-patients.
- Diversified Cash Flow Structure:
- In addition to traditional pharmaceutical sales, Fosun utilizes license-out mechanisms to license early-stage innovative technologies to major global pharma companies, securing upfront payments, R&D milestone payments, and sales royalties—becoming a key supplementary source of cash flow and profit.
- Global Manufacturing and Export: By acquiring manufacturers with global GMP certification standards like Gland Pharma, it uses them as the core of its global supply chain to export products to Europe, the United States, and emerging markets.
II. Development Strategy: The 4IN Strategy
The core of the company’s overall strategy is “4IN,” designed to support its internationalization and professionalization:
- Innovation:
- Shifting from “fast follower” to “original R&D.” Focusing on cutting-edge technology platforms such as small molecules, monoclonal antibodies, cell immunotherapies (CAR-T), and mRNA, and utilizing AI-assisted drug screening to improve R&D efficiency and precision.
- Internationalization:
- Expanding beyond product sales globalization into the globalization of its R&D and production systems. By establishing manufacturing bases in the US, Europe, and India, it utilizes local pharmaceutical regulations and talent advantages to deeply cultivate global markets.
- Intelligentization:
- Implementing digital and intelligent transformations. Utilizing big data and AI in the drug discovery stage, promoting smart factories on the manufacturing side, and optimizing digital supply chain monitoring on the management side to reduce operational costs and improve decision-making quality.
- Integration:
- Strengthening resource allocation within the group. Achieving synergy across R&D, manufacturing, commercialization, and medical services departments, and continually reinforcing key nodes in the industry chain through mergers and acquisitions to maximize synergistic effects across business segments.
Back to Fosun pharma